(Q42657229)

4 November 2017

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. (English)

1 reference

4 November 2017

1 reference

1 reference

Zobair M Younossi

1

1 reference

4 November 2017

Arthur C McCullough

2

1 reference

4 November 2017

David S Barnes

3

1 reference

4 November 2017

Anthony Post

4

1 reference

4 November 2017

Janus P Ong

5

1 reference

4 November 2017

Robert O'Shea

6

1 reference

4 November 2017

Lisa M Martin

7

1 reference

4 November 2017

Diane Bringman

8

1 reference

4 November 2017

Denise Farmer

9

1 reference

4 November 2017

Gavin Levinthal

10

1 reference

4 November 2017

Kevin D Mullen

11

1 reference

4 November 2017

William D Carey

12

1 reference

4 November 2017

Anthony S Tavill

13

1 reference

4 November 2017

Roy Ferguson

14

1 reference

4 November 2017

Terry Gramlich

15

1 reference

4 November 2017

1 May 2005

1 reference

Digestive Diseases and Sciences

4 November 2017

1 reference

4 November 2017

50

1 reference

4 November 2017

5

1 reference

4 November 2017

970-975

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-005-2673-y

4 November 2017

0 references

cites work

The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

12 December 2020

Standards of treatment in chronic hepatitis C.

1 reference

12 December 2020

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

12 December 2020

Interferon-alpha-2b and ribavirin for retreatment of chronic hepatitis C.

1 reference

12 December 2020

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

1 reference

12 December 2020

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

1 reference

12 December 2020

Course and outcome of hepatitis C

1 reference

12 December 2020

Hepatitis C: an update on the silent epidemic

1 reference

12 December 2020

Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.

1 reference

12 December 2020

Treatment strategies for hepatitis C: making the best of limited options

1 reference

12 December 2020

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

12 December 2020

Retreatment of patients with chronic hepatitis C.

1 reference

12 December 2020

Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.

1 reference

12 December 2020

10.1007/S10620-005-2673-Y

Identifiers

DOI

1 reference

4 November 2017

1 reference